AFM28

AFM28 monotherapy receives authorization of a Clinical Trial Application (CTA) for the phase 1 study by the French National Agency for the Safety of Medicines and Health Products…

AFM28 efficiently directs allogeneic NK cells to CD123-positive leukemic cells, including leukemic stem and progenitor cells, inducing their depletion in samples of patients with Acute…

AFM28 induced potent, effective, and specific anti-tumor activity against CD123-positive cells irrespective of mutational statusStudy demonstrated specific anti-tumor response even at low…

AFM28 effectively induces depletion of leukemic cells in patient bone marrow samples and demonstrates the anticipated good safety profile and pharmacologic activity in cynomolgus…